Icotinib bei NSCLC-Patienten mit EGFR-Mutationen: Chinesische Eigenentwicklung will auf den Weltmarkt

2012 ◽  
Vol 03 (05) ◽  
pp. 208-208
Author(s):  
Alexander Kretzschmar
Keyword(s):  
Clinical Oncology ◽  
Chinese Society ◽  
Sich Eine

Mit Icotinib schickt sich eine weitere, gegen Mutationen des EGF-Rezeptors (EGFRm+) gerichtete Therapie des nicht-kleinzelligen Lungenkarzinoms (NSCLC) an, nach China auch die Zulassung in Europa und USA zu erreichen. Dies berichtete Dr. Sun Yan, Beijing, kürzlich auf der 15. Jahrestagung der Chinese Society of Clinical Oncology (CSCO). Dafür sind allerdings noch einige Verbesserungen am Studiendesign, vor allem bei der molekularen Charakterisierung der Patienten, notwendig, kritisierte Prof. Tony Mok, Honkong.

scholarly journals Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer (2020 version)

2020 ◽  
Vol 1 ◽  
pp. 27-27
Author(s):  
Zefei Jiang ◽  
Erwei Song ◽  
Xiaojia Wang ◽  
Haibo Wang ◽  
Xiang Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Oncology ◽  
Diagnosis And Treatment ◽  
Chinese Society

scholarly journals The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021

2021 ◽  
Author(s):  
Feng‐Hua Wang ◽  
Xiao‐Tian Zhang ◽  
Yuan‐Fang Li ◽  
Lei Tang ◽  
Xiu‐Juan Qu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Oncology ◽  
Clinical Guidelines ◽  
Diagnosis And Treatment ◽  
Chinese Society

scholarly journals The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma

2021 ◽  
Author(s):  
Ling‐Long Tang ◽  
Yu‐Pei Chen ◽  
Chuan‐Ben Chen ◽  
Ming‐Yuan Chen ◽  
Nian‐Yong Chen ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Clinical Oncology ◽  
Clinical Guidelines ◽  
Diagnosis And Treatment ◽  
Chinese Society

scholarly journals Attitudes and Practices of Immune Checkpoint Inhibitors in Chinese Patients With Cancer: A National Cross-Sectional Survey

2021 ◽  
Vol 12 ◽  
Author(s):  
Luping Zhang ◽  
Jun Wang ◽  
Bicheng Zhang ◽  
Qian Chu ◽  
Chunxia Su ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Clinical Oncology ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Tumor Volume ◽  
Checkpoint Inhibitors ◽  
Chinese Society ◽  
Expert Committee ◽  
Cross Sectional Survey ◽  
Cross Sectional

Immune-checkpoint inhibitors (ICIs) are revolutionizing the field of immuno-oncology. Side effects and tumor microenvironment currently represent the most significant obstacles to using ICIs. In this study, we conducted an extensive cross-sectional survey to investigate the concept and practices regarding the use of ICIs in cancer patients in China. The results provide real-world data on the adverse events (AEs) of ICIs and the factors influencing the use of ICIs. This survey was developed by the Expert Committee on Immuno-Oncology of the Chinese Society of Clinical Oncology (CSCO-IO) and the Expert Committee on Patient Education of the Chinese Society of Clinical Oncology (CSCO-PE). The surveys were distributed using a web-based platform between November 29, 2019 and December 21, 2019. A total of 1,575 patients were included. High costs (43.9%), uncertainty about drug efficacy (41.2%), and no reimbursement from medical insurance (32.4%) were the factors that prevented the patients from using ICIs. The patients were most concerned about the onset time or effective duration of ICIs (40.3%), followed by the indications of ICIs and pre-use evaluation (33.4%). Moreover, 9.0, 57.1, 21.0, and 12.9% of the patients reported tumor disappearance, tumor volume reduction, no change in tumor volume, and increased tumor volume. Among the patients who received ICIs, 65.7% reported immune-related AEs (irAEs); 96.1% reported mild-to-moderate irAEs. Cancer patients in China had a preliminary understanding of ICIs. Yet, the number of patients treated with ICIs was small.

Sign in / Sign up

Export Citation Format

Share Document